Abstract
Synthetic advances made possible chemical assembly of complex oligosaccharide fragments of polysaccharide domains on the surface of human pathogenic bacteria. These oligosaccharides may be recognized by antibodies raised against high molecular weight, native, polysaccharides. In addition to their antigenicity, synthetic oligosaccharides can also function as haptens in their protein conjugates that can elicit not only oligo- but also polysaccharide-specific IgG antibodies in animal models and in humans. A major milestone in the development of new generation vaccines was the demonstration that protein conjugates of synthetic fragments of the capsular polysaccharide of Haemophilus influenzae type b are as efficacious in preventing childhood meningitis and other diseases as is the corresponding licensed commercial vaccine containing the bacterial polysaccharide. The lessons learnt in this and other endeavors described herein are manifold. For example, they teach us about the significance of the oligosaccharide epitope size, the number of their copies per protein in the conjugate, the possible effect of the spacer on anti-saccharide immune response, and the proper choice of the carrier protein combined with the selection of the animal model. The H. influenzae b story also teaches us that that the synthetic approach can be commercially viable.
Keywords: Haemophilus influenzae, oligosaccharides, Shigella Dysenteriae Type 1, Streptococcus Pneumoniae, keyhole limpet hemocyanin
Current Topics in Medicinal Chemistry
Title: Recent Developments in Synthetic Oligosaccharide-Based Bacterial Vaccines
Volume: 8 Issue: 2
Author(s): Vince Pozsgay
Affiliation:
Keywords: Haemophilus influenzae, oligosaccharides, Shigella Dysenteriae Type 1, Streptococcus Pneumoniae, keyhole limpet hemocyanin
Abstract: Synthetic advances made possible chemical assembly of complex oligosaccharide fragments of polysaccharide domains on the surface of human pathogenic bacteria. These oligosaccharides may be recognized by antibodies raised against high molecular weight, native, polysaccharides. In addition to their antigenicity, synthetic oligosaccharides can also function as haptens in their protein conjugates that can elicit not only oligo- but also polysaccharide-specific IgG antibodies in animal models and in humans. A major milestone in the development of new generation vaccines was the demonstration that protein conjugates of synthetic fragments of the capsular polysaccharide of Haemophilus influenzae type b are as efficacious in preventing childhood meningitis and other diseases as is the corresponding licensed commercial vaccine containing the bacterial polysaccharide. The lessons learnt in this and other endeavors described herein are manifold. For example, they teach us about the significance of the oligosaccharide epitope size, the number of their copies per protein in the conjugate, the possible effect of the spacer on anti-saccharide immune response, and the proper choice of the carrier protein combined with the selection of the animal model. The H. influenzae b story also teaches us that that the synthetic approach can be commercially viable.
Export Options
About this article
Cite this article as:
Pozsgay Vince, Recent Developments in Synthetic Oligosaccharide-Based Bacterial Vaccines, Current Topics in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/156802608783378864
DOI https://dx.doi.org/10.2174/156802608783378864 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Current Vascular Pharmacology Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Targeting the Chemokine Receptor CXCR3 and Its Ligand CXCL10 in the Central Nervous System: Potential Therapy for Inflammatory Demyelinating Disease?
Current Neurovascular Research Tuberculosis - Present Medication and Therapeutic Prospects
Current Medicinal Chemistry Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Characterization and antiherpetic activity of native and chemically sulfated polysaccharide from <i>Adenanthera pavonina</i>
Current Pharmaceutical Biotechnology Management of Tuberculosis in Children and New Treatment Options
Infectious Disorders - Drug Targets Structural Biology of Bacterial Secretion Systems in Gram-Negative Pathogens- Potential for New Drug Targets
Infectious Disorders - Drug Targets Ceftriaxone-Vancomycin Drug Toxicity Reduction by VRP 1020 in Mus musculus Mice
Current Clinical Pharmacology Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
CNS & Neurological Disorders - Drug Targets Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews Activin and TGF-β Effects on Brain Development and Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Genome Variability in Gram-Positive Pathogenic Bacteria - Impact on Virulence and Evolution
Current Genomics Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine <i>In Vitro</i> Characteristics of Glioma Cells Targeting by OX26-modified Liposomal Cisplatin
Letters in Drug Design & Discovery Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Occurrence of blaTEM and blaROB in Haemophilus species Causing Respiratory Tract Infections
Infectious Disorders - Drug Targets